Home > Insider Trading > Filing (0001209191-20-055590)

Filing Details

Accession Number:: 0001209191-20-055590
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-10-22 17:36:19
Reporting Period:: 2020-10-20

Accepted Time:: 2020-10-22 17:36:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348911	Kalvista Pharmaceuticals Inc.	KALV	Pharmaceutical Preparations (2834)	200915291

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1691102	Christopher Yea	C/O Kalvista Pharmaceuticals, Inc 55 Cambridge Parkway, Suite 901E Cambridge MA 02142	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2020-10-20	5,640	$17.27	76,315	No	4	S	Direct
Common Stock	Disposition	2020-10-20	2,302	$18.01	74,013	No	4	S	Direct
Common Stock	Disposition	2020-10-21	3,500	$17.68	70,513	No	4	S	Direct
Common Stock	Disposition	2020-10-21	2,544	$19.02	67,969	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to$17.92 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of theSecurities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price withinthe range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to$18.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of theSecurities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price withinthe range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.21 to $18.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.